These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52 related articles for article (PubMed ID: 1392155)
21. Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. Repetto L; Miglietta L; Gardin G; Naso C; Giudici S; Merlini L; Queirolo P; Campora E; Pronzato P; Rosso R Ann Oncol; 1992 Feb; 3(2):165-6. PubMed ID: 1606088 [TBL] [Abstract][Full Text] [Related]
22. Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. Hausmaninger H; Lehnert M; Steger G; Sevelda P; Tschurtschenthaler G; Hehenwarter W; Fridrik M; Samonigg H; Schiller L; Manfreda D Eur J Cancer; 1995 Dec; 31A(13-14):2169-73. PubMed ID: 8652237 [TBL] [Abstract][Full Text] [Related]
23. Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial. Lyss AP; Luedke SL; Einhorn L; Luedke DW; Raney M Oncology; 1989; 46(6):357-9. PubMed ID: 2511534 [TBL] [Abstract][Full Text] [Related]
25. Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. Panasci L; Shenouda G; Begin L; Pollak M; Reinke A; Margolese R Cancer Chemother Pharmacol; 1990; 26(6):457-60. PubMed ID: 2121379 [TBL] [Abstract][Full Text] [Related]
26. High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer. Falkson CI; Falkson HC; Falkson G Am J Clin Oncol; 1988 Aug; 11(4):431-4. PubMed ID: 2970218 [TBL] [Abstract][Full Text] [Related]
27. Failure of mitomycin-vindesine combination chemotherapy as salvage treatment for metastatic breast cancer. Ardizzoni A; Pronzato P; Canobbio L; Lionetto R; Rosso R J Cancer Res Clin Oncol; 1985; 110(1):77-8. PubMed ID: 4019571 [TBL] [Abstract][Full Text] [Related]
28. Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity. Perren TJ; Blackledge G; Mould JJ; Chetiyawardana AD; Morrison M; Hancock A Invest New Drugs; 1985; 3(2):173-7. PubMed ID: 3926713 [TBL] [Abstract][Full Text] [Related]
29. Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. Gridelli C; Pepe R; Airoma G; Incoronato P; Rossi A; Palazzolo G; Bianco AR Tumori; 1992 Dec; 78(6):380-2. PubMed ID: 1297232 [TBL] [Abstract][Full Text] [Related]
30. Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. Stein RC; Bower M; Law M; Bliss JM; Barton C; Gazet JC; Ford HT; Coombes RC Eur J Cancer; 1992; 28A(12):1963-5. PubMed ID: 1419290 [TBL] [Abstract][Full Text] [Related]
31. Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study. Atiba JO; Green SJ; Hynes HE; Osborne CK; Miller TP; Davidner M Invest New Drugs; 1994; 12(2):129-32. PubMed ID: 7860229 [TBL] [Abstract][Full Text] [Related]
32. 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. Sato K; Hiraide H; Tamakuma S; Tabei T; Maruyama M; Touma M; Okamura H; Matsumoto F; Akao S; Ishikawa H; Yagi Y; Mochizuki H Breast Cancer; 2001; 8(1):58-62. PubMed ID: 11180767 [TBL] [Abstract][Full Text] [Related]
33. Mitoxantrone, 5-fluorouracil and levo-leucovorin as salvage treatment in advanced breast cancer patients. Mammoliti S; Merlini L; Caroti C; Gallo L Eur J Cancer; 1994; 30A(2):248-9. PubMed ID: 8155400 [No Abstract] [Full Text] [Related]
34. The modulating effects of flurbiprofen on adriamycin plus vincristine or vindesine in the treatment of advanced breast cancer. Perez DJ; Powles TJ; Smith IE; Vincent MD; Ashley S; Gordon C; Gibb J; Clarke S; Coombes RC Cancer Chemother Pharmacol; 1985; 15(3):278-82. PubMed ID: 3902268 [TBL] [Abstract][Full Text] [Related]
35. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Montes A; Powles TJ; O'Brien ME; Ashley SE; Luckit J; Treleaven J Eur J Cancer; 1993; 29A(13):1854-7. PubMed ID: 8260241 [TBL] [Abstract][Full Text] [Related]
36. A phase II study with mitomycin and vindesine in metastatic pretreated breast cancer. Hupperets PS; Fickers MM; Schouten LJ; Blijham GH Eur J Cancer; 1991; 27(4):520-1. PubMed ID: 1827735 [No Abstract] [Full Text] [Related]
38. Combination chemoendocrine therapy containing vindesine for refractory metastatic breast cancer. Maemura M; Iino Y; Yokoe T; Takei H; Horiguchi J; Horii Y; Nagasawa M; Takeyoshi I; Ohwada S; Morishita Y Oncol Rep; 1997; 4(4):799-802. PubMed ID: 21590143 [TBL] [Abstract][Full Text] [Related]
39. Weekly vindesine as second-line chemotherapy in pediatric low-grade glioma. Zhang A; Wang X; Chan GCF; Liu APY; Gao Y Childs Nerv Syst; 2024 Nov; 40(11):3477-3479. PubMed ID: 39085625 [No Abstract] [Full Text] [Related]
40. [A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers]. Degardin M; Hecquet B; Bonneterre J; Adenis A; Pion JM; Demaille A Bull Cancer; 1992; 79(2):169-76. PubMed ID: 1392155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]